Step-by-step guides, research summaries, and treatment overviews β reviewed by oncology navigators and written clearly for patients, families, and caregivers.
From newly diagnosed to relapsed and refractory β we publish what patients actually need to understand their options.
What are you looking for today?
CancerFax Insights exists because cancer patients face decisions that are genuinely hard β not because of lack of will, but because the information landscape is fragmented, fast-moving, and often written for clinicians, not families.
Every insight published here is reviewed by our oncology navigation team before it goes live. We focus on the questions patients actually ask us: What is this treatment? Who qualifies? What should I prepare? What should I ask my doctor?
Use the search and filters below to find what's most relevant to your situation.
Step-by-step patient guide
Before agreeing to CAR-T therapy, families need to understand eligibility criteria, the manufacturing timeline, expected side effects, and what happens if the therapy fails. This guide walks through every question your team should be able to answer.
Browse by the topic most relevant to where you are in your cancer journey right now.
Compare options, evaluate trade-offs, understand what questions to ask before agreeing to a specific protocol.
How trial matching works, eligibility logic explained, document checklists, and what to expect during screening.
NGS testing, biomarker-based treatment matching, liquid biopsy, tumour mutation burden, and targeted therapy guides.
Cross-border treatment pathways, China and India access, visa planning, cost estimates, and logistics walk-throughs.
Practical guides for families, partners, and adult children walking alongside someone in cancer treatment.
How to prepare records, frame clinical questions, compare opinions, and navigate specialist review across borders.
Search, filter, and explore all published insights β by cancer type, treatment category, clinical trial readiness, or stage of your journey.
Search across cancer types, treatments, mutations, drugs, and trials
Second Opinion
A cancer second opinion involves having a second specialist review your diagnosis, pathology, staging, and treatment plan β studies show it changes management in 30β50% of cases and is recommended by oncologists worldwide before starting any major cancer treatment.
CancerFax Services
CancerFax is a specialist cancer access and patient-navigation platform that helps patients and families worldwide understand their options, access second opinions, and connect with leading oncology centres in China, India, and beyond β particularly for advanced, rare, or treatment-resistant cancers.
CancerFax Services
A second opinion in oncology β an independent review of your diagnosis, pathology, and treatment plan by a specialist not involved in your current care β changes or significantly refines the treatment recommendation in 30β40% of cancer cases, and is particularly valuable for rare cancers, complex treatment decisions, and patients considering advanced therapy options.
Cancer Surgery
"Unresectable" is not always a permanent verdict. Studies consistently show that 10β20% of patients labelled unresectable by their local oncologist are found to be resectable β or convertible to resectability β when reviewed by a subspecialty surgical oncologist at a high-volume centre. A remote surgical second opinion typically requires 5β7 business days and imaging review only β no travel needed at the assessment stage.
insight
When cancer progresses after treatment, the first step is to confirm what βprogressionβ means in your case. Doctors usually review recent scans, symptoms, blood tests, tumor markers, pathology, prior treatments, and sometimes new biopsy or biomarker testing. Progression may lead to a change in treatment, local therapy for selected sites, supportive care, clinical trial screening, or a second opinion. Biomarker testing may help identify targeted therapy, immunotherapy, or trial options for some patients with advanced or recurrent cancer.[1] Canc
Rare Cancer Treatments
Second opinions matter more for rare cancers because the gap between general oncology and specialist rare tumour centre expertise is larger. A specialist review covers pathology re-examination, molecular testing completeness, and treatment recommendation. Chinese academic centres (CAMS, FUSCC) provide both remote and in-person second opinions with 2β3 week turnaround.
Pediatric Cancer Advanced Therapy
Major international centres: St. Jude (Global Alliance in 70+ countries), CHOP, Seattle Childrens, Dana-Farber (North America); Great Ormond Street, Gustave Roussy, Princess Maxima Center (Europe); NCC Singapore, Seoul National University Childrens (Asia-Pacific); King Faisal, Sheba (Middle East). Virtual second opinions increasingly accessible.
Stage 4 Cancer
International treatment access is relevant for three stage 4 patient groups: those in countries where a specific approved therapy is unavailable or unaffordable; those whose relevant clinical trial has no domestic site; and those seeking second opinions from centres with specialist expertise in their cancer type. The answer is not always to travel to the US -- international centres of excellence exist in the UK, Germany, Israel, South Korea, Singapore, and India.
CAR-T Cell Therapy
Key CAR-T questions: Why CAR-T now? Which product and why? What are your centre's outcomes? What happens if manufacturing fails? What are Grade 3-4 CRS/ICANS rates? What are my alternatives? Should I get a second opinion?
Where are you in your cancer journey? Find insights matched to your current situation.
Understand your diagnosis, staging, reports, and first-line options before making major decisions.
Read newly-diagnosed insightsExplore second opinions, molecular testing, clinical trials, and international advanced options.
Explore next-step insightsLearn how trial matching, eligibility review, and mutation-based screening actually work.
View clinical trial insightsUnderstand how destination, treatment availability, cost, and expertise shape cross-border decisions.
Compare destinationsCurated reading lists for patients going deep into a specific treatment category or clinical question.
Cell & gene therapy
Precision oncology
Advanced radiation & local therapies
Explore insights and guides organised by the treatment modality most relevant to your case.
Find content specific to your diagnosis β from treatment overviews to clinical trial access and second opinion guidance.
Clinical trial access
CancerFax connects patients with clinical trials in China, India, and leading global centres β including phase I and II trials closed to international enrolment through standard channels.
500+
active clinical trials across China, India, and leading global centres
40+
cancer types with current advanced therapy access pathways
12+
years of patient navigation experience in cross-border oncology
Insights our navigation team recommends most often to patients starting their research.
Treatment guide Β· 8 min
02Second opinion Β· 6 min
03Precision oncology Β· 10 min
04Clinical trials Β· 7 min
05Clinical trials Β· 9 min
06Precision oncology Β· 5 min
A note from the CancerFax team
CancerFax Insights is editorially independent of the hospitals, pharmaceutical companies, and treatment centres we work with. Our navigation team writes what patients need to hear β not what any institution wants them to read.
That means we tell patients when a treatment is likely out of reach, when a clinical trial has closed, and when the evidence for a new therapy is still thin. We believe informed patients make better decisions and have better outcomes β even when the honest answer is harder to hear.
β CancerFax oncology navigation team
How our content is produced, reviewed, and how to use it effectively.
Our oncology navigators review your medical records, explain your options in plain language, and help you access the right specialists, trials, and treatment centres β wherever you are in the world.
Every navigation request is reviewed by a qualified oncology professional. We do not recommend treatments without reviewing your medical records.
